Return Peptide Library
Amycretin
ALevel 1 evidenceAmycretin
Amylin analog
Basic Information
Categories
GLP-1/amylin dual receptor agonist
Overview
Novo Nordisk's single-molecule dual GLP-1/amylin receptor agonist delivers significant weight loss results.
Efficacy Rating
Weight loss, in research, GLP-1
Evidence Level
Grade A
Evidence Type
No data available
Confidence
No data available
China Regulatory Status
Cosmetic Ingredient Directory
No data available
Food/Supplements
No data available
Medicine
No data available
Similar Peptide Recommendations
Cagrilintide
Cagrilintide
AAmylin analog
Weight loss, metabolic health, in research
Retatrutide
Retatrutide
AGLP-1 and incretin receptor agonists
Weight loss, in research, GLP-1
Survodutide
Survodutide
AGLP-1 and incretin receptor agonists
Weight loss, in research, GLP-1
ASC36
ASC36
DAmylin analog
Research on amylin and obesity
Disclaimer
The content on this platform is for educational and informational purposes only and does not constitute medical advice, formulation guidance, or a guarantee of regulatory compliance. All efficacy claims are labeled with their evidence level; please consult a professional before making any decisions.